BeiGene (China) Today

688235 Stock   166.43  0.03  0.02%   

Performance

4 of 100

 
Weak
 
Strong
Insignificant

Odds Of Distress

Less than 34

 
High
 
Low
Below Average
BeiGene is trading at 166.43 as of the 25th of November 2024, a 0.02% up since the beginning of the trading day. The stock's open price was 166.4. BeiGene has about a 34 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for BeiGene are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
BeiGene is entity of China. It is traded as Stock on SHG exchange. The company has 115.06 M outstanding shares. More on BeiGene

Moving together with BeiGene Stock

  0.89601336 New China LifePairCorr

BeiGene Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BeiGene's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BeiGene or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CoChairman CoFounderXiaodong Wang
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors)
BeiGene's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to BeiGene's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
BeiGene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BeiGene's financial leverage. It provides some insight into what part of BeiGene's total assets is financed by creditors.
Liquidity
BeiGene cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. BeiGene has accumulated 688.37 M in total debt. Debt can assist BeiGene until it has trouble settling it off, either with new capital or with free cash flow. So, BeiGene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BeiGene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BeiGene to invest in growth at high rates of return. When we think about BeiGene's use of debt, we should always consider it together with cash and equity.

Change To Inventory

(133.9 Million)
BeiGene (688235) is traded on Shanghai Stock Exchange in China and employs 10,600 people. BeiGene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 153.61 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BeiGene's market, we take the total number of its shares issued and multiply it by BeiGene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BeiGene operates under Biotechnology sector and is part of Health Care industry. The entity has 115.06 M outstanding shares. BeiGene generates negative cash flow from operations
Check BeiGene Probability Of Bankruptcy
Ownership Allocation
BeiGene holds a total of 115.06 Million outstanding shares. 30% of BeiGene outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BeiGene Ownership Details

BeiGene Risk Profiles

Although BeiGene's alpha and beta are two of the key measurements used to evaluate BeiGene's performance over the market, the standard measures of volatility play an important role as well.

BeiGene Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in BeiGene without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Transaction History Now

   

Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Module

BeiGene Corporate Management

Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Chan LeeGeneral VPProfile
Titus BallVP OfficerProfile
Yang JiChief OfficerProfile
Liza HeapesHead RelationsProfile
Wang LaiGlobal RDProfile
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.